Genetic changes of non-small cell lung cancer under neoadjuvant therapy.

ABSTRACT:

Background

Large scale sequencing efforts defined common molecular alterations in non-small cell lung cancer (NSCLC) and revealed potentially druggable mutations. Yet, systematic data on the changes of the respective molecular profiles under standard therapy in NSCLC are limited.

Results

14 out of 68 observed coding mutations (21%) and 6 out of 33 (18%) copy number variations (CNV) were lost or gained during therapy. Mutational and CNV changes clustered in 6/37 (16%) and 3/37 (8%) patients. Changes in clinically relevant mutations were rare but present in single cases for genes such as BRAF and PIK3CA. The type of radiochemotherapy but not the duration of therapy impacted on the frequency of mutational changes.

Methods

We established a lung cancer specific next-genera

SUBMITTER: Warth A 

PROVIDER: S-EPMC5045431 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature